Roth Resumes Coverage On Fibrocell With Buy Rating, $7 Target
May 24, 2016 at 09:28 AM EDT
Fibrocell Science Inc (NASDAQ: FCSC) is leveraging its expertise with fibroblasts to target monogenic diseases as well as broader ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.